Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Usha Panneerselvam

Internal Medicine Cranston, RI Medical Doctor

NPI 1114944006 CMS profile 793604

351 Budlong Road, Cranston, RI 02920

Open in the dashboard

General payments

$7,184

389 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Usha Panneerselvam of Cranston, RI is reported in the CMS Open Payments database as having received $7,184 across 389 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $33 1
2022 General $728 41
2021 General $2,175 123
2020 General $1,792 93
2019 General $2,455 131

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Usha Panneerselvam
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Usha Panneerselvam were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Usha Panneerselvam Internal Medicine median Middle half National median
2019 $2,455 $159 $48–$570 $163
2020 $1,792 $119 $33–$402 $114
2021 $2,175 $135 $37–$521 $132
2022 $728 $141 $42–$496 $149
2023 $33 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $971 35 payments
  2. Novo Nordisk Inc $908 41 payments
  3. AbbVie, Inc. $599 29 payments
  4. GlaxoSmithKline, LLC. $599 37 payments
  5. Pfizer Inc. $522 44 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $502 24 payments
  7. Lilly USA, LLC $422 29 payments
  8. AstraZeneca Pharmaceuticals LP $345 23 payments
  9. Sanofi-Aventis U.S. LLC $271 15 payments
  10. Mylan Specialty L.P. $196 10 payments
  11. Other $1,850 102 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $7,155 386 payments
  2. Education $29 3 payments
Products named General payments · program years 2019–2023
  1. XARELTO $836 33 payments
  2. INVOKANA $410 18 payments
  3. Ozempic $383 23 payments
  4. RYBELSUS $354 17 payments
  5. JARDIANCE $316 14 payments
  6. TRELEGY ELLIPTA $278 18 payments
  7. SPIRIVA RESPIMAT $240 13 payments
  8. NURTEC ODT $215 9 payments
  9. ELIQUIS $214 16 payments
  10. Xultophy 100/3.6 $193 7 payments
  11. Other $6,164 384 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

389 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record